연구성과로 돌아가기

2024 연구성과별 연구자 정보 (1630 / 2344)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC Kim, Jehun Kim, J 16 Kosin Univ, Coll Med, Dept Internal Med, Busan, South Korea ejspulm@pusan.ac.kr;fireajh@gmail.com;
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC Park, Jin-Han Park, JH 17 Inje Univ, Coll Med, Dept Internal Med, Busan, South Korea ejspulm@pusan.ac.kr;fireajh@gmail.com;
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC Kim, Tae Hoon Kim, TH 18 Gyeongsang Natl Univ, Sch Med, Dept Internal Med, Chang Won, South Korea GXF-5826-2022 kim, Tae-hoon ejspulm@pusan.ac.kr;fireajh@gmail.com;
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC Kim, Tae Hoon Kim, TH 18 Gyeongsang Natl Univ, Changwon Hosp, Chang Won, South Korea GXF-5826-2022 kim, Tae-hoon ejspulm@pusan.ac.kr;fireajh@gmail.com;
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC Eom, Jung Seop Eom, JS 19 교신저자 Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, 179 Gudeok Ro, Busan 49241, South Korea ejspulm@pusan.ac.kr;fireajh@gmail.com;
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC Ahn, June Hong Ahn, JH 20 교신저자 Yeungnam Univ, Coll Med, Dept Internal Med, Daegu, South Korea AAB-3093-2019 Ahn, June ejspulm@pusan.ac.kr;fireajh@gmail.com;
PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration Kim, Juhee Kim, J 1 Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Ophthalmol, Daegu, South Korea smpark93@gmail.com;DongHo_Park@knu.ac.kr;
PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration Kim, Juhee Kim, J 1 Kyungpook Natl Univ, Cell & Matrix Res Inst, Daegu, South Korea smpark93@gmail.com;DongHo_Park@knu.ac.kr;
PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration Jeon, Yujin Jeon, Y 2 Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Ophthalmol, Daegu, South Korea smpark93@gmail.com;DongHo_Park@knu.ac.kr;
PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration Jeon, Yujin Jeon, Y 2 Kyungpook Natl Univ, Cell & Matrix Res Inst, Daegu, South Korea smpark93@gmail.com;DongHo_Park@knu.ac.kr;
PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration Son, Jinyoung Son, J 3 Kyungpook Natl Univ, Grad Sch, Dept Biomed Sci, Daegu, South Korea smpark93@gmail.com;DongHo_Park@knu.ac.kr;
PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration Son, Jinyoung Son, J 3 BK21 FOUR KNU Convergence Educ Program Biomed Sci, Daegu, South Korea smpark93@gmail.com;DongHo_Park@knu.ac.kr;
PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration Pagire, Haushabhau S. Pagire, HS 4 Gwangju Inst Sci & Technol, Dept Chem, Gwangju, South Korea smpark93@gmail.com;DongHo_Park@knu.ac.kr;
PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration Pagire, Haushabhau S. Pagire, HS 4 JD Biosci Inc, R&D Ctr, Gwangju, South Korea smpark93@gmail.com;DongHo_Park@knu.ac.kr;
PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration Pagire, Suvarna H. Pagire, SH 5 Gwangju Inst Sci & Technol, Dept Chem, Gwangju, South Korea smpark93@gmail.com;DongHo_Park@knu.ac.kr;
페이지 이동: